Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

NCT00910858 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00910858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00910858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Lead sponsor
Celgene Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2005
Completion date
May 31, 2009
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

low- or intermediate-1-risk myelodysplastic syndrome (mds)